Vylor (VYLR) is positioned as the only scaled pure-play seed and genetics company, with a strong germplasm library and top US corn and soybean brands, Oppenheimer said in a Tuesday note.

The report said Vylor enters its first year as a standalone with some 27% operating EBITDA margins, and a licensing business that turns net positive in 2027 for the first time.

"We see low-single-digit sales growth compounding into high-single-digit EBITDA growth, with gene editing and hybrid wheat as longer-dated options not in the numbers," the report said.

The note pointed to improved cash flow visibility, favorable near-term setup, and scarcity value that support 18 times multiple.

Oppenheimer initiated coverage of the stock with an outperform rating and an $82 price target.

Price: 73.30, Change: -0.03, Percent Change: -0.04